Chemours (CC)
(Delayed Data from NYSE)
$19.79 USD
-0.66 (-3.23%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $19.80 +0.01 (0.05%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth C Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$19.79 USD
-0.66 (-3.23%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $19.80 +0.01 (0.05%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth C Momentum F VGM
Zacks News
Chemours (CC) Q2 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Chemours (CC) delivered earnings and revenue surprises of -20.00% and -7.97%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Chemours (CC) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Chemours (CC) is expected to see some pressure on Ti-Pure TiO2 volumes in Q2.
Earnings Preview: Chemours (CC) Q2 Earnings Expected to Decline
by Zacks Equity Research
Chemours (CC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Chemours Inaugurates Opteon Facility, Boosts Production
by Zacks Equity Research
Chemours' (CC) new Texas-based facility will triple its production capacity of Opteon YF, which minimizes greenhouse gases.
Chemours (CC) Down 35% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Chemours (CC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Chemours' Opteon Refrigerants Selected by MEHITS Applications
by Zacks Equity Research
Chemours' (CC) Opteon XL41 is an A2L class refrigerant that offers the lowest GWP replacement solution.
Broad Markets Slide Again on Trade Woes
by David Borun
During a typically a slow week, US equities gave up ground again ans US-China trade talks stall
Zacks Value Trader Highlights: General Motors, General Electric, Chemours, Camping World and L Brands
by Zacks Equity Research
Zacks Value Trader Highlights: General Motors, General Electric, Chemours, Camping World and L Brands
Cheap Stock or Value Trap?
by Tracey Ryniec
How to spot value trap stocks.
Chemours' Opteon XL Selected by Carrier Transicold Europe
by Zacks Equity Research
Chemours' (CC) Opteon low GWP HFO refrigerants are a portfolio of versatile and sustainable refrigerants.
Chemours' (CC) Earnings, Revenues Trail Estimates in Q1
by Zacks Equity Research
Lower volumes in the Titanium Technologies unit and higher costs hurt Chemours' (CC) Q1 results.
This Week's Must-See Earnings Charts
by Tracey Ryniec
Which stocks will traders be watching this busy earnings week? These are some of those at the top of the list.
Earnings Preview: Chemours (CC) Q1 Earnings Expected to Decline
by Zacks Equity Research
Chemours (CC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Chemours' (CC) Opteon XP40 Refrigerant Selected by E-mart
by Zacks Equity Research
Chemours' (CC) Opteon XP40 refrigerant is expected to improve energy efficiency in E-mart stores.
Is Chemours (CC) a Suitable Stock for Value Investors Now?
by Zacks Equity Research
Let's see if Chemours (CC) stock is a good choice for value-oriented investors right now from multiple angles.
Chemours (CC) Down 2.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Chemours (CC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
With Equities on a Roll in 2019, a Quiet Week Leads to More Gains
by David Borun
The rally rolls on during a holiday-shortened week
Chemours (CC) Q4 Earnings In Line, Revenues Trail Estimates
by Anindya Barman
Lower volumes affected Chemours' (CC) results in Q4. The company sees adjusted earnings per share in the range of $4.00-$5.05 for 2019.
Chemours (CC) to Post Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Our proven model does not show that Chemours (CC) is likely to beat estimates this quarter.
Friday Rally Helps the Markets Recover Earlier Weekly Losses
by David Borun
Positive earnings data and an end to the government shutdown help keep the 2019 rally gooing
Solid Gains Top Another Wild Week
by David Borun
A big selloff on Thursday is followed by an even bigger rally on Friday.
Chemours' Opteon XL41 Chosen by Carrier to Replace R-410A
by Zacks Equity Research
Chemours (CC) is committed to deliver world-class technology that reduces impact on global climate change.
Why Is Chemours (CC) Down 18.5% Since Last Earnings Report?
by Zacks Equity Research
Chemours (CC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Chemours (CC) to Increase Prices of Methylamines Products
by Zacks Equity Research
Chemours' (CC) latest price hike is likely to support its margins.
Chemours (CC) Q3 Earnings Beat, Revenues Trail Estimates
by Zacks Equity Research
Chemours' (CC) Q3 results benefits from strong demand in Fluoroproducts and higher global average selling prices in Titanium Technologies.